Compare Inovio Pharmaceuticals Inc (INO) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Microsoft — how do they compare? Inovio Pharmaceuticals Inc trades at $1.11 (market cap $119.42M), while Microsoft trades at $527.5 (market cap $3.93T). The key difference: Microsoft is far larger — about 32909.1× Inovio Pharmaceuticals Inc's market cap, and Microsoft pays a 0.74% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Microsoft for 142 Days on average.
| INO | MSFT | |
|---|---|---|
Market Cap | $119.42M | $3.93T |
Volume | 2,789,649 | 16,040,951 |
Sector | Health | Technology |
52-Week High | $2.65 | $542.07 |
52-Week Low | $0.66 | $352.83 |
Typical Hold Time | 43 Days | 142 Days |
Enterprise Value | $90.75M | $3.91T |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 3.54% on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $84.95 million in 2025 on minimal revenue of $65,340, with negative profitability metrics, but has beaten EPS estimates in recent quarters. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107.
The investment case hinges on regulatory approval of INO-3107, with a consensus price target of $2.75 implying significant upside. However, extreme financial losses, high cash burn, and dependence on dilutive financing pose substantial risks. Analyst sentiment is cautiously optimistic but reflects high uncertainty.
Microsoft (MSFT) trades at $529.76, up 0.09% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.74 exceeding the $4.24 forecast. Revenue and net income have shown robust growth, reaching $281.72B and $101.83B in 2025, respectively. Analyst consensus is overwhelmingly positive, with 82% buy ratings and a $571.76 price target, indicating potential upside from current levels.
The outlook for MSFT remains favorable due to its leadership in AI and cloud computing, though risks include heightened capital expenditure concerns and competitive pressures. The stock's valuation multiples, such as a P/E of 29.51, reflect premium pricing but are supported by high profitability margins and growth prospects. Investors should weigh the strong institutional support against macroeconomic and sector-specific volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
